Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
KRX:207940
Price:
784 000 KRW
0.38%
Market Closed
Updated:
May 16, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
34.3
Current
58.4
Median
17.5
Industry
Lower
than median
Higher
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=34.3
Enterprise Value
/
54.9T
EBITDA
1.6T
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
55.8T KRW | 34.3 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
231.6B USD | 23.8 | |
| US |
|
Danaher Corp
NYSE:DHR
|
195.1B USD | 17.5 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
45.2B USD | 29.1 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
42.4B USD | 16.9 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
38.2B CHF | 20 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
32.5B USD | 28.4 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
26.6B USD | 17.5 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
25.7B USD | 31.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
21.5B USD | 23.8 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
18.1B EUR | 30.7 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
32.5
2-Years Forward
EV/EBITDA
28.2
3-Years Forward
EV/EBITDA
22.9
You don't have any saved screeners yet
